Hot flashes get most of the airtime, but postmenopause hormone therapy touches almost every major organ system over years, advanced hormone therapy not weeks. Deciding whether to start, continue, or stop hormone replacement therapy in the postmenopausal years is less about a single guideline and more about matching a person’s goals, risks, and timeline with the right formulation, dose, and route. I have sat with patients who only wanted two more hours of sleep per night, others who feared a hip fracture because their mother lost independence after one, and others who wanted their sex life back. The best plan folds those priorities into the clinical realities we know from trials and long follow-up.
The frame that actually matters: timing, dose, and route
Three variables do most of the heavy lifting when you look at long-term risk and benefit with postmenopause hormone therapy, often called HRT or menopause hormone therapy.
Timing first. Data over the last two decades supports a timing hypothesis: initiating estrogen therapy close to the final menstrual period, typically within 10 years or before age 60, tends to produce a more favorable cardiovascular and overall risk profile than starting later. The same dose that looks neutral or beneficial at 54 may look riskier when first started at 68. That is not dogma, it reflects vascular biology, plaque stability, and thrombotic risk that evolve with age.
Dose next. Use the lowest dose that controls target symptoms and protects the endometrium when a uterus is present. Minimal effective dose is not a cliché; it materially changes the odds of venous thromboembolism, stroke, and breast tenderness, and it helps compliance. With transdermal estradiol, for instance, many women do well at 25 to 50 micrograms twice weekly. Others need 75 micrograms for six months, then down-titrate. You do not win prizes for staying high.
Route finally. Oral and transdermal estrogen are not interchangeable with regard to clot risk and triglycerides. Oral estradiol passes through the liver, increasing clotting factors and sex hormone binding globulin; transdermal estradiol avoids first-pass metabolism, usually resulting in fewer swings in triglycerides and a lower thrombotic signal. For a woman with migraine with aura or a strong family history of venous clots, I favor transdermal estrogen if we treat at all.
Estrogen alone versus estrogen and progesterone
For women without a uterus, estrogen therapy alone is typically used. For those with an intact uterus, a progestogen is required to prevent endometrial hyperplasia and cancer. Body and brain sometimes respond differently to these combinations. Micronized progesterone, taken orally at night, often improves sleep and has a more favorable metabolic and breast profile compared to some synthetic progestins. A common and well-tolerated approach is transdermal 17-beta estradiol with oral micronized progesterone 100 mg nightly or 200 mg for 12 to 14 days each month if using a cyclic regimen.
I often see women who tried medroxyprogesterone acetate in the past and stopped due to mood changes or breast tenderness. Swapping to micronized progesterone can change the whole experience. The principle is simple: match physiology where possible and monitor how the individual feels and functions.
What the long arc looks like: symptom relief now, bone and urogenital health later
Vasomotor symptoms usually improve within 2 to 6 weeks on a stable dose. Night sweats resolve first, then daytime hot flashes. Sleep deepens, especially if progesterone is part of the regimen. Energy and cognition follow a quieter curve, generally improving as sleep stabilizes. Libido can improve as sleep and mood lift and as vaginal tissues respond to estrogen. In postmenopause, the urogenital tract remains estrogen dependent for life, so even after systemic therapy ends, many women stay on local vaginal estrogen or DHEA to maintain comfort with sex, reduce recurrent UTIs, and improve pelvic floor symptoms.
Bone is the other long-tail benefit. Estrogen slows bone resorption, stabilizing bone mineral density and reducing fracture risk while you are on it. After discontinuation, the protective effect wanes over 1 to 2 years. That means systemic estrogen is a bone-preserving therapy while in use, not a one-and-done solution. If a patient stops systemic HRT after several years and has osteopenia, we talk about calcium intake, resistance training, vitamin D sufficiency, and whether to add a bone agent like a bisphosphonate or a sclerostin inhibitor based on her DEXA trajectory and fracture risk.
Cardiovascular health: nuance beats headlines
Many women come in with a memory of the early 2000s headlines that cast HRT as dangerous. Those headlines were based on trials that enrolled women well past the menopausal transition, with an average starting age in the mid-60s. When we apply contemporary evidence with the timing principle, the story is subtler.
In women who start within 10 years of menopause and are younger than 60, standard-dose estrogen therapy, particularly transdermal, is generally neutral for heart disease risk and may reduce coronary calcification progression in some subgroups. The risk of venous clots is still present, especially with oral routes and higher doses, but absolute risk in a healthy 55-year-old nonsmoker remains small. Stroke risk rises with age, dose, and oral route. That is one reason I dissuade a first start at 68 unless the symptom burden is severe and nonhormonal options fail.
Lipid effects vary by formulation. Oral estrogen tends to lower LDL cholesterol and raise HDL while increasing triglycerides. Transdermal estradiol has a smaller impact on triglycerides and clotting factors. For women with hypertriglyceridemia or a family history of early venous thrombosis, transdermal makes sense if we use systemic therapy.
Blood pressure typically does not change meaningfully with low-dose transdermal therapy. I still recommend home measurements for the first two months in anyone with borderline hypertension because small increases can push someone over a threshold for treatment.
Breast cancer: risk depends on type, time, and baseline
Breast risk is the subject that most often stops a conversation. The reality is more granular. Estrogen alone, in women without a uterus, has not been associated with an increased risk of breast cancer in long-term follow-up and may show a small reduction. Combined estrogen and progestogen therapy has been associated with a small increase in breast cancer risk with longer durations of use, and the signal appears to depend in part on the progestogen used, the dose, and duration beyond about 3 to 5 years. The absolute numbers matter. In many risk calculators, the excess cases per 1,000 women over 5 years of combined therapy are in the low single digits, and that risk is lower if a woman starts near menopause rather than later.
Family history changes how we read those numbers. A woman with a BRCA mutation or strong family clustering of breast cancer deserves a different approach, often avoiding systemic combined therapy and focusing on nonhormonal strategies plus local vaginal estrogen for genitourinary symptoms if needed. Regular mammography remains essential whether on HRT or not, and dense breast tissue may nudge us to add ultrasound or MRI based on risk scoring.
Cognition and mood: set realistic expectations
Estrogen is not a dementia prevention drug. Starting systemic HRT late, well past menopause, has not shown cognitive benefit and may increase dementia risk in some analyses. Initiating therapy around the menopausal transition does not appear to harm cognition, and some women report fewer word-finding issues and better concentration as sleep and vasomotor symptoms improve. That is an indirect benefit via better sleep and reduced stress reactivity.
For mood, perimenopause is the highest-risk window for new or worsened anxiety and depression. By postmenopause, the acute hormonal volatility has calmed, but residual insomnia and hot flashes still fuel mood symptoms. In my practice, the most robust mood improvements come from two places: better sleep via symptom control and the judicious use of antidepressants or psychotherapy when needed. If a patient has persistent depression independent of vasomotor symptoms, I do not rely on HRT as the primary treatment.
Urogenital health: local therapy has outsized value
Genitourinary syndrome of menopause includes dryness, burning, dyspareunia, urinary urgency, frequency, and recurrent UTIs. Systemic estrogen helps, but local estrogen in the form of a low-dose vaginal tablet, ring, or cream delivers targeted relief with negligible systemic absorption. Women can safely use local estrogen for years, even decades, including many breast cancer survivors under oncologist guidance. Vaginal DHEA is another option for tissue health and sexual comfort. For many patients, long-term health considerations include planning to keep local therapy in place even if systemic therapy is tapered off later.
Testosterone in postmenopausal women: narrow lane, careful driving
Testosterone therapy, often marketed as low T treatment or testosterone optimization, is everywhere online. Evidence-based use in women is narrower than the marketing suggests. The clearest indication is hypoactive sexual desire disorder in postmenopausal women, after other contributors like medication side effects, relationship stress, vaginal pain, or depression have been addressed. When used, the goal is to restore blood levels to the premenopausal female physiologic range, not to male norms. In the United States there is no FDA-approved testosterone product for women, so clinicians use low-dose transdermal formulations off label, or compounded bioidentical hormones in carefully calibrated doses. Over-treatment can cause acne, hirsutism, voice changes, and lipid shifts. Regular monitoring matters.
I advise against pellet hormone therapy for testosterone in women because the dose cannot be adjusted once implanted and side effects can persist for months. The same caution applies to high-dose compounded bioidentical hormones when they are not titrated to measured hormone levels and clinical response. Bioidentical does not mean risk-free, and natural hormone therapy is only as safe as the dose, route, and oversight allow.
Compounded versus FDA-approved options
Compounded hormone therapy has a place when a patient needs a dose or formulation that is not commercially available, for example, when a patient has a contact allergy to an excipient. For most women, FDA-approved estradiol patches, gels, sprays, and oral micronized progesterone provide predictable dosing, known safety profiles, and insurance coverage. If a patient chooses compounded bioidentical hormones, we discuss quality variability between pharmacies and the importance of symptom tracking and lab monitoring, because the product is not standardized the way a branded estradiol patch is.
Who should not use systemic HRT
Below is a concise reference I use when weighing absolute contraindications to systemic therapy. Local vaginal estrogen is often still acceptable, but systemic forms are generally avoided.
- History of estrogen-sensitive breast cancer or endometrial cancer without oncology clearance Active or prior venous thromboembolism, stroke, or known thrombophilia Coronary event or stroke within the past year, or uncontrolled hypertension Unexplained vaginal bleeding, or untreated endometrial hyperplasia Severe active liver disease
These are starting points. There are edge cases, such as a woman 20 years out from a treated early-stage estrogen receptor positive breast cancer, struggling with debilitating vasomotor symptoms. In those scenarios, I coordinate closely with oncology and consider nonhormonal agents first.
Nonhormonal therapies worth knowing
Some women either cannot or prefer not to take hormones. Nonhormonal options have improved, and they matter for long-term quality of life. Selective serotonin reuptake inhibitors and SNRIs reduce hot flashes in many patients within 1 to 2 weeks. Gabapentin helps night sweats and sleep at bedtime doses. Oxybutynin helps vasomotor symptoms for some women. Fezolinetant, an oral neurokinin 3 receptor antagonist, is a newer option specifically for moderate to severe vasomotor symptoms and does not act as a hormone. For bone health, bisphosphonates, denosumab, romosozumab, and teriparatide address different risk levels and timelines. Pelvic floor therapy, vaginal moisturizers, and lubricants help sexual comfort and urinary symptoms when hormones are off the table.
Practical monitoring and follow-up
I usually map out the first six months so patients know what to expect. Start with a baseline visit that documents symptoms, blood pressure, BMI, family history, and breast and pelvic screening status. Obtain baseline labs when they will inform safety or adherence: fasting lipids for those with cardiovascular risk, A1c for those at risk for diabetes, and thyroid function if symptoms overlap or if the patient is on thyroid hormone replacement. Hormone levels are rarely needed for estradiol in standard dosing, but progesterone adherence can be checked clinically by bleeding patterns or via endometrial thickness if indicated.
A simple follow-up rhythm helps:
- Four to eight weeks after starting or changing dose to assess symptom response, blood pressure, and side effects Every six to twelve months once stable, to review ongoing need, adjust dose, and update breast and bone screening DEXA every one to two years in women with osteopenia or risk factors Consider liver function and triglycerides if on oral estrogen or with baseline abnormalities
Women on testosterone therapy require additional checks for total testosterone, SHBG, lipids, and observation for androgenic side effects. Those on compounded formulations need extra attention because dose drift can occur.
" width="560" height="315" style="border: none;" allowfullscreen="" >
Duration and how to stop
There is no arbitrary expiration date on postmenopause hormone therapy. Duration should be personalized. Some women use systemic therapy for three to five years to cover the intense vasomotor period, then step down to local vaginal therapy. Others with severe osteoporosis risk or persistent symptoms may continue longer at the lowest effective dose, reassessing each year. The small breast risk associated with longer combined therapy should be part of that discussion.
Discontinuation can be abrupt or tapered. I find that tapering the estrogen dose over one to three months reduces the chance of rebound hot flashes, particularly in women who had severe symptoms before. A practical taper with a 50 microgram patch is to step down to 37.5, then 25, then 12.5 micrograms every two to four weeks while maintaining progesterone if the uterus is intact until the estrogen has stopped. Keep local vaginal therapy ongoing as needed.
Real-world trade-offs
Consider two patients. Elena, 56, entered menopause at 52 and is tormented by night sweats. She is healthy, a nonsmoker, blood pressure 118 over 72, LDL 110, BMI 24. A transdermal estradiol patch at 50 micrograms and oral micronized progesterone 100 mg nightly changed her sleep within a month. Her hot flashes fell from 10 daily to two, both mild. At her six-month check, we lowered the patch to 37.5 micrograms with no loss of control. Her mammogram was normal. At year three, she still sleeps well but wants to come off. We tapered over three months. She stayed on a low-dose vaginal estradiol tablet twice weekly and remains symptom controlled.
Now, Dana, 67, presents a decade into menopause with new hot flashes after stopping long-term paroxetine. She has a sister who had a pulmonary embolus at 62 and a personal history of migraine with aura. Her DEXA shows osteopenia. For Dana, oral estrogen is a poor fit. Starting systemic HRT at 67 is also higher risk. We restarted an SSRI at a lower dose, added local vaginal estrogen for dryness, doubled down on strength training and protein for bone health, and after a careful discussion, added a bisphosphonate given her FRAX score. Her flashes calmed within two weeks, and she avoided a new systemic hormone start at a later age.
These cases are common and illustrate how nuance guides safer choices. The same protocols do not suit everyone.
Where pellet implants, injections, and shortcuts go wrong
Hormone pellet implants and high-dose injections promise convenience: no daily pill, no patch changes. The cost is loss of control. If a patient develops breast tenderness, mood swings, or elevated hematocrit on a pellet, the drug is already under the skin for months. I have managed women whose testosterone levels were three to four times the desired female range for more than six months after pellets. That is a hard detour to reverse. A safer version of convenience is a transdermal patch for estrogen and capsules for progesterone, both of which can be titrated week to week if needed.
How to think about bioidentical hormones without the hype
Bioidentical hormones like 17-beta estradiol and micronized progesterone match molecules the body produces. Many FDA-approved options use these molecules. That is the bioidentical most women want, not a bespoke compounded cream with unverified potency. Compounded bioidentical hormones enter the picture when a very specific dose or combination is clinically required. If you pursue compounded therapy, work with a hormone specialist or endocrinologist who can coordinate hormone testing and treatment, document symptom changes, and keep a tight feedback loop. The endgame is not a specific brand, it is steady symptom control and minimized risk.
Special notes for complex histories
Autoimmune disease, migraine, prior gestational diabetes, and thyroid disease each add wrinkles.
Migraine with aura increases stroke risk independent of hormones. If HRT is used, transdermal low-dose estradiol is preferred, and some women feel better with continuous rather than cyclic progesterone to reduce hormonal swings.
Type 2 diabetes or metabolic syndrome raises baseline cardiovascular risk. Transdermal estrogen is usually the safer route, and attention to hormone therapy triglycerides matters. Interestingly, some women see improved insulin sensitivity with symptom control and better sleep, but I do not count on that to manage diabetes.
Hypothyroidism on levothyroxine can require a dose adjustment when starting oral estrogen because SHBG and thyroid binding globulin rise. Transdermal routes cause fewer binding changes, but I still check TSH 6 to 8 weeks after significant HRT changes.
Cancer survivorship requires tailored decisions. Many estrogen receptor positive breast cancer survivors can use local vaginal estrogen safely in consultation with their oncology team. Systemic therapy is more constrained and usually avoided unless quality-of-life threats are severe and nonhormonal options have failed.
Building a plan you can live with
The best HRT plan fits into a patient’s life without constant friction. Here is a short checklist I use to align treatment with long-term health.
- Clarify primary goals: sleep, hot flashes, sexual comfort, bone health, or mood Choose the safest effective route based on risk: often transdermal for systemic needs, local for urogenital Start low, then review symptoms at 4 to 8 weeks and adjust Keep screening current: mammogram, colon cancer screening, DEXA when indicated Reassess annually whether to continue, reduce dose, or transition to nonhormonal or local therapy
Hormone therapy for women after menopause is not a forever decision locked in at the first prescription. It is a living plan. Good care means revisiting the why, not just the what, and staying honest about changing risks as birthdays accumulate. Whether you work with an internist, gynecologist, or an endocrinologist experienced in hormone balance therapy, insist on a conversation that blends symptom relief with the long view. The aim is not maximal hormones or maximal restraint, it is a durable fit for the body you inhabit now and the health you want over the next decade.